BioSpace News Archive

NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference.

Intelligent Bio Solutions Inc., announced that its Board of Directors has cancelled the Company’s annual meeting of stockholders that was originally scheduled to be held on June 16, 2022, but was adjourned several times due to lack of quorum.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results of RELIEF-PHN-1, its Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in the UK.

Precision Medicine Asia Co., Ltd. and National Cancer Center Hospital East announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific, a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

OKYO Pharma Limited announced that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at the event and online.

Osivax announced the Last Patient Last Visit in two Phase 2a clinical trials evaluating Osivax’ lead T-cell based, broad-spectrum influenza vaccine candidate, OVX836.

ADC Therapeutics SA and Swedish Orphan Biovitrum AB announced the European Commission has granted conditional marketing authorization for the use of ZYNLONTA® for the treatment of relapsed or refractory diffuse large B-cell lymphoma.